NA Internal Neurostimulation Devices Market - Industry Trends Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143146
- Pages: 225
-
Format:
Short Description:
North America Internal Neurostimulation Devices Market, By Product Type (Spinal Cord Stimulation (SCS), Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, and Gastric Electric Stimulation), Distribution Channel (Direct Tender and Third Party Service Provider), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2029
Market Definition:
An internal neurostimulation device is a surgically placed device. It delivers mild electrical signals to the epidural space near your spine through one or more thin wires called leads. Neurostimulation provides pain relief by disrupting the pain signals traveling between the spinal cord and the brain.
Neurostimulation devices include invasive and noninvasive approaches involving electrical stimulation to drive neural function within a circuit. The increased demand for internal neurostimulation devices is due to next-generation technological progressions in the neurostimulation devices, providing much-needed therapeutic relief to an unprecedented number of people affected by debilitating neurologic and psychiatric disorders worldwide. The rise of modern-day neuromodulation therapies has increased over half a century, rich with serendipitous discoveries and technological advances that have led to different neurostimulation strategies. Within the past two decades, innovation in medical device technology has begun to drive the evolution of these neurostimulation systems at a more accelerated pace
The convenient internal neurostimulation device used by the patients is vagus nerve stimulation. The vagus neurostimulation device uses a device to stimulate the vagus nerve with electrical impulses. An implantable vagus nerve stimulator is currently FDA-approved to treat epilepsy and depression. There's one vagus nerve on each side of the body, running from the brainstem through the neck to the chest and abdomen. In the future, software advancements such as closed-loop stimulation and remote programming will enable internal neurostimulation devices to be a more personalized and accessible technology. The future of internal neurostimulation devices is expected to improve quality of life further.
Market Segmentation:
The North America internal neurostimulation devices market is categorized into product type and distribution channel.
On the basis of product type, the North America internal neurostimulation devices market is segmented into spinal cord stimulation (SCS), deep brain stimulation, vagus nerve stimulation, sacral nerve stimulation, gastric electric stimulation
On the basis of distribution channel, the North America internal neurostimulation devices market is segmented into direct tender and third party service provider
Market Players:
Some key market players operating in the North America internal neurostimulation devices market are listed below:
Medtronic
LivaNova PLC
Abbott
ONWARD
Sequana Medical NV
CIRTEC
Valencia Technologies
Nalu Medical, Inc.
NEVRO CORP.
Stimwave LLC
MicroTransponder Inc.
Newronika S.p.A.
Microsemi (a subsidiary of Microchip Technology Inc.)
Boston Scientific Corporation
Inspire Medical Systems, Inc
Integer Holdings Corporation
BlueWind Medical
Micro-Leads
Axonics, Inc.
TABLE OF CONTENTS
1 INTRODUCTION 66
1.1 OBJECTIVES OF THE STUDY 66
1.2 MARKET DEFINITION 66
1.3 OVERVIEW OF NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET 66
1.4 CURRENCY AND PRICING 69
1.5 LIMITATION 69
1.6 MARKETS COVERED 69
2 MARKET SEGMENTATION 74
2.1 MARKETS COVERED 74
2.2 GEOGRAPHIC SCOPE 75
2.3 YEARS CONSIDERED FOR THE STUDY 76
2.4 CURRENCY AND PRICING 76
2.5 RESEARCH METHODOLOGY 77
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 80
2.7 DBMR MARKET POSITION GRID 81
2.8 THE CATEGORY VS TIME GRID 83
2.9 SECONDARY SOURCES 84
2.10 ASSUMPTIONS 84
3 EXECUTIVE SUMMARY 85
4 PREMIUM INSIGHTS 87
4.1 PESTEL 88
4.2 PORTER'S FIVE FORCES MODEL 89
4.3 PIPELINE ANALYSIS FOR INTERNAL NEUROSTIMULATION DEVICES MARKET 90
5 REGULATIONS OF NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET 92
6 EPIDEMIOLOGY OF DISEASES 94
6.1 INCIDENCE OF ISCHEMIA 94
6.2 INCIDENCE OF PARKINSON'S DISEASE 94
6.3 INCIDENCE OF FAILED BACK SYNDROME 95
6.4 INCIDENCE OF TREMOR 95
6.5 INCIDENCE OF DEPRESSION 96
6.6 INCIDENCE OF URINE INCONTINENCE 96
6.7 INCIDENCE OF FECAL INCONTINENCE 97
6.8 INCIDENCE RATE OF EPILEPSY 97
6.9 INCIDENCE OF GASTROPARESIS 98
6.10 PREVALENCE OF OBESITY 99
7 EPIDEMIOLOGY OF NEUROSTIMULATION PROCEDURES 101
7.1 NUMBER OF SPINAL CORD STIMULATION (SCS) PROCEDURES 101
7.1.1 NUMBER OF TEST PROCEDURES 101
7.1.2 NUMBER OF IMPLANTATION PROCEDURES 101
7.2 NUMBER OF DEEP BRAIN STIMULATION PROCEDURES 101
7.3 NUMBER OF VAGUS NERVE STIMULATION PROCEDURES 101
7.4 NUMBER OF SACRAL NEVER STIMULATION PROCEDURES 102
7.5 NUMBER OF TRANSCRANIAL MAGNETIC STIMULATION (TMS) PROCEDURES 102
7.6 NUMBER OF INTERMITTENT THETA BURST STIMULATION (ITBS) PROCEDURES 102
7.7 NUMBER OF TRANSCRANIAL DIRECT ELECTRICAL STIMULATION (TDCS) PROCEDURES 103
8 MARKET OVERVIEW 104
8.1 DRIVERS 106
8.1.1 RISE IN PREVALENCE AND INCIDENCE OF NEUROLOGICAL DISORDERS 106
8.1.2 DEMAND FOR INTERNAL NEUROSTIMULATION DEVICES AS A ADD ON THERAPY 107
8.1.3 INCREASED FUNDING FOR THE NEUROSTIMULATION DEVICES 107
8.1.4 TECHNOLOGICAL ADVANCEMENTS IN THE INTERNAL NEUROSTIMULATION DEVICES 107
8.1.5 RISE IN PRODUCT APPROVALS 108
8.2 RESTRAINTS 109
8.2.1 RISE IN COST OF THE DEEP BRAIN STIMULATION DEVICES 109
8.2.2 RISKS NOTICED WHILE USING THE INTERNAL NEUROSTIMULATION DEVICES 109
8.2.3 RISE IN PRODUCT RECALL 109
8.2.4 AVAILABILITY OF ALTERNATE IMAGING DIAGNOSTIC DEVICES 110
8.3 OPPORTUNITIES 110
8.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 110
8.3.2 RECENT PRODUCT DEVELOPMENTS IN THE INTERNAL NEUROSTIMULATION DEVICES 111
8.3.3 DEMAND FOR MINIMALLY INVASIVE SURGERY 111
8.4 CHALLENGES 112
8.4.1 RISKS ASSOCIATED WITH THE IMPLANTATION OF THESE DEVICES 112
8.4.2 LACK OF SKILLED HEALTHCARE PROFESSIONALS 112
9 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE 113
9.1 OVERVIEW 114
9.2 SPINAL CORD STIMULATION 117
9.2.1 SPINAL CORD STIMULATION, BY TYPE 118
9.2.1.1 BATTERY 118
9.2.1.1.1 RECHARGEABLE 119
9.2.1.1.2 NON-RECHARGEABLE 119
9.2.1.2 LEAD 119
9.2.1.2.1 PERCUTANEOUS 120
9.2.1.2.2 PADDLE 120
9.2.2 SPINAL CORD STIMULATION, BY APPLICATION 120
9.2.2.1 ISCHEMIA 120
9.2.2.2 CHRONIC LOW BACK PAIN (CLBP) 120
9.2.2.3 DIABETIC NEUROPATHY 121
9.2.2.4 FAILED BACK SYNDROME 121
9.3 DEEP BRAIN STIMULATION 121
9.3.1 DEEP BRAIN STIMULATION, BY TYPE 122
9.3.1.1 SINGLE CHANNEL DEEP BRAIN STIMULATOR 123
9.3.1.2 DOUBLE CHANNEL DEEP BRAIN STIMULATOR 123
9.3.1.3 BATTERY 123
9.3.1.3.1 RECHARGEABLE 124
9.3.1.3.2 NON-RECHARGEABLE 124
9.3.1.4 LEAD 124
9.3.2 DEEP BRAIN STIMULATION, BY APPLICATION 124
9.3.2.1 PARKINSONS DISEASE 125
9.3.2.2 TREMOR 125
9.3.2.3 DEPRESSION 125
9.4 SACRAL NERVE STIMULATION 125
9.4.1 SACRAL NERVE STIMULATION, BY TYPE 126
9.4.1.1 BATTERY 127
9.4.1.2 LEAD 127
9.5 SACRAL NERVE STIMULATION, BY APPLICATION 127
9.5.1 URINE INCONTINENCE 127
9.5.2 FECAL INCONTINENCE 128
9.6 VAGUS NERVE STIMULATION 128
9.6.1 VAGUS NERVE STIMULATION, BY TYPE 129
9.6.1.1 BATTERY 130
9.6.1.2 LEAD 130
9.6.2 VAGUS NERVE STIMULATION, BY APPLICATION 130
9.6.2.1 EPILEPSY 130
9.6.2.2 OTHERS 130
9.7 GASTRIC ELECTRICAL STIMULATION 130
9.7.1 GASTRIC ELECTRICAL STIMULATION, BY TYPE 131
9.7.1.1 BATTERY 132
9.7.1.2 LEAD 132
9.7.2 GASTRIC ELECTRICAL STIMULATION, BY APPLICATION 132
9.7.2.1 GASTROPARESIS 133
9.7.2.2 OTHERS 133
10 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET, BY DISTRIBUTION CHANNEL 134
10.1 OVERVIEW 135
10.2 DIRECT TENDER 137
10.3 THIRD PARTY PROVIDER 138
11 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET, BY REGION 140
11.1 NORTH AMERICA 141
11.1.1 U.S. 153
11.1.2 CANADA 161
11.1.3 MEXICO 169
12 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: COMPANY LANDSCAPE 177
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 177
13 SWOT ANALYSIS 178
14 COMPANY PROFILE 179
14.1 MEDTRONIC (2021) 179
14.1.1 COMPANY SNAPSHOT 179
14.1.2 REVENUE ANALYSIS 179
14.1.3 COMPANY SHARE ANALYSIS 180
14.1.4 PRODUCT PORTFOLIO 180
14.1.5 RECENT DEVELOPMENTS 181
14.2 BOSTON SCIENTIFIC CORPORATION (2021) 182
14.2.1 COMPANY SNAPSHOT 182
14.2.2 REVENUE ANALYSIS 183
14.2.3 COMPANY SHARE ANALYSIS 183
14.2.4 PRODUCT PORTFOLIO 184
14.2.5 RECENT DEVELOPMENTS 184
14.3 ABBOTT (2021) 186
14.3.1 COMPANY SNAPSHOT 186
14.3.2 REVENUE ANALYSIS 186
14.3.3 COMPANY SHARE ANALYSIS 187
14.3.4 PRODUCT PORTFOLIO 187
14.3.5 RECENT DEVELOPMENTS 188
14.4 LIVANOVA PLC (2021) 189
14.4.1 COMPANY SNAPSHOT 189
14.4.2 REVENUE ANALYSIS 189
14.4.3 COMPANY SHARE ANALYSIS 190
14.4.4 PRODUCT PORTFOLIO 190
14.4.5 RECENT DEVELOPMENTS 190
14.5 NEVRO CORP. (2021) 192
14.5.1 COMPANY SNAPSHOT 192
14.5.2 REVENUE ANALYSIS 192
14.5.3 COMPANY SHARE ANALYSIS 193
14.5.4 PRODUCT PORTFOLIO 193
14.5.5 RECENT DEVELOPMENTS 194
14.6 AXONICS, INC. 195
14.6.1 COMPANY SNAPSHOT 195
14.6.2 REVENUE ANALYSIS 195
14.6.3 PRODUCT PORTFOLIO 196
14.6.4 RECENT DEVELOPMENTS 196
14.7 ALEVA NEUROTHERAPEUTICS 197
14.7.1 COMPANY SNAPSHOT 197
14.7.2 PRODUCT PORTFOLIO 197
14.7.3 RECENT DEVELOPMENTS 197
14.8 BIONIC VISION TECHNOLOGIES. 198
14.8.1 COMPANY SNAPSHOT 198
14.8.2 PRODUCT PORTFOLIO 198
14.8.3 RECENT DEVELOPMENTS 198
14.9 BLUEWIND MEDICAL 199
14.9.1 COMPANY SNAPSHOT 199
14.9.2 PRODUCT PORTFOLIO 199
14.9.3 RECENT DEVELOPMENTS 199
14.10 BIOINDUCTION 200
14.10.1 COMPANY SNAPSHOT 200
14.10.2 PRODUCT PORTFOLIO 200
14.10.3 RECENT DEVELOPMENT 200
14.11 CIRTEC 201
14.11.1 COMPANY SNAPSHOT 201
14.11.2 PRODUCT PORTFOLIO 201
14.11.3 RECENT DEVELOPMENTS 202
14.12 FINETECH MEDICAL 203
14.12.1 COMPANY SNAPSHOT 203
14.12.2 PRODUCT PORTFOLIO 203
14.12.3 RECENT DEVELOPMENTS 203
14.13 GIMER MEDICAL 204
14.13.1 COMPANY SNAPSHOT 204
14.13.2 PRODUCT PORTFOLIO 204
14.13.3 RECENT DEVELOPMENTS 204
14.14 INSPIRE MEDICAL SYSTEMS, INC. 205
14.14.1 COMPANY SNAPSHOT 205
14.14.2 REVENUE ANALYSIS 205
14.14.3 PRODUCT PORTFOLIO 206
14.14.4 RECENT DEVELOPMENTS 206
14.15 INTEGER HOLDINGS CORPORATION 207
14.15.1 COMPANY SNAPSHOT 207
14.15.2 REVENUE ANALYSIS 207
14.15.3 PRODUCT PORTFOLIO 208
14.15.4 RECENT DEVELOPMENT 208
14.16 INBRAIN NEUROELECTRONICS 209
14.16.1 COMPANY SNAPSHOT 209
14.16.2 PRODUCT PORTFOLIO 209
14.16.3 RECENT DEVELOPMENT 209
14.17 MAINSTAY MEDICAL 210
14.17.1 COMPANY SNAPSHOT 210
14.17.2 REVENUE ANALYSIS 210
14.17.3 PRODUCT PORTFOLIO 211
14.17.4 RECENT DEVELOPMENTS 211
14.18 MICROSEMI (A WHOLLY OWNDED SUBSIDIARY OF MICROCHIP TECHNOLOGY INC.) 212
14.18.1 COMPANY SNAPSHOT 212
14.18.2 REVENUE ANALYSIS 212
14.18.3 PRODUCT PORTFOLIO 213
14.18.4 RECENT DEVELOPMENTS 213
14.19 MICROTRANSPONDER INC 214
14.19.1 COMPANY SNAPSHOT 214
14.19.2 PRODUCT PORTFOLIO 214
14.19.3 RECENT DEVELOPMENT 214
14.20 MICRO-LEADS 215
14.20.1 COMPANY SNAPSHOT 215
14.20.2 PRODUCT PORTFOLIO 215
14.20.3 RECENT DEVELOPMENT 215
14.21 NALU MEDICAL, INC 216
14.21.1 COMPANY SNAPSHOT 216
14.21.2 PRODUCT PORTFOLIO 216
14.21.3 RECENT DEVELOPMENT 216
14.22 NEURONANO AB 217
14.22.1 COMPANY SNAPSHOT 217
14.22.2 PRODUCT PORTFOLIO 217
14.22.3 RECENT DEVELOPMENTS 217
14.23 NEURIMPULSE S.R.L. 218
14.23.1 COMPANY SNAPSHOT 218
14.23.2 PRODUCT PORTFOLIO 218
14.23.3 RECENT DEVELOPMENTS 218
14.24 NEWRONIKA S.P.A. 219
14.24.1 COMPANY SNAPSHOT 219
14.24.2 PRODUCT PORTFOLIO 219
14.24.3 RECENT DEVELOPMENTS 219
14.25 OPTOGENTECH GMBH. 220
14.25.1 COMPANY SNAPSHOT 220
14.25.2 PRODUCT PORTFOLIO 220
14.25.3 RECENT DEVELOPMENTS 220
14.26 ONWARD 221
14.26.1 COMPANY SNAPSHOT 221
14.26.2 PRODUCT PORTFOLIO 221
14.26.3 RECENT DEVELOPMENT 221
14.27 STIMWAVE LLC (2021) 222
14.27.1 COMPANY SNAPSHOT 222
14.27.2 PRODUCT PORTFOLIO 222
14.27.3 RECENT DEVELOPMENTS 222
14.28 SEQUANA MEDICAL NV (2021) 223
14.28.1 COMPANY SNAPSHOT 223
14.28.2 REVENUE ANALYSIS 223
14.28.3 PRODUCT PORTFOLIO 224
14.28.4 RECENT DEVELOPMENTS 224
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
